Search clinical trials for: BI 11634 ER formulation M

Total 90 results

Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, Portugal, Bulgaria
AstraZeneca

Completed

To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers

Parkinson's Disease

United Kingdom
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Terminated

Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
Dr Phillip J Buckhurst
BMI Southend Hospital

Completed

Clinical Investigation of the Bi Flex M Multifocal IOL

Cataract
Boehringer Ingelheim

Completed

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Healthy
Mylan Inc.
Mylan GmbH

Completed

Mylan Insulin Glargine Study

Diabetes Mellitus, Type 1

United States
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Healthy

Germany
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Healthy

Germany
Chinese University of Hong Kong

Completed

Herbal Treatment for Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Hong Kong
Impax Laboratories, LLC

Completed

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States
GlaxoSmithKline
London School of Hygiene and Tropical Medicine; PATH; Medical Research Council... and other collaborators

Completed

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Infections, Streptococcal

Gambia
OPKO Health, Inc.

Completed

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Covid19 | Coronavirus | SARS-CoV-2 Infection

United States
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
Bayer

Completed

Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

Toothache

United States
Sun Yat-sen University

Recruiting

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

Hepatocellular Carcinoma Recurrent

China
University of Pennsylvania

Recruiting

Ibudilast for Treating Alcohol Use Disorder (Ibudilast)

Alcoholism | Alcohol Use Disorder (AUD)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States
Idorsia Pharmaceuticals Ltd.

Terminated

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Healthy Subjects

France
Stanford University

Completed

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

Breast - Female

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group; American College of Radiology Imaging Network

Completed

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Acute Myeloid Leukemia | Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Plasma Cell Myeloma | Myelodysplastic/Myeloproliferative Neoplasm | Graft Versus Host Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States, Italy
National Cancer Institute (NCI)
NRG Oncology; Radiation Therapy Oncology Group

Completed

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States, Canada, Israel
National Cancer Institute (NCI)

Completed

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
National Cancer Institute (NCI)

Completed

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Pineoblastoma | Recurrent Medulloblastoma | Refractory Medulloblastoma | Refractory Peripheral Primitive Neuroectodermal Tumor | Central Nervous System Neoplasm | Recurrent Primitive Neuroectodermal Tumor

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Completed

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Cerebral Anaplastic Astrocytoma | Cerebral Astrocytoma | Childhood Cerebellar Anaplastic Astrocytoma

United States, Canada
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

B-Cell Non-Hodgkin Lymphoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States

Search clinical trials for: BI 11634 ER formulation M

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations